EU and US could reach trade deal this weekend - Reuters
Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a company based in Dallas, Texas, with a market capitalization of approximately $598 million, announced Monday that its stockholders have approved an amendment to the company’s Amended and Restated Certificate of Incorporation. This amendment increases the authorized number of common stock shares from 400 million to 700 million. The decision was made during the company’s 2025 annual meeting of stockholders held on June 2, 2025. The amendment was filed with the Secretary of State of Delaware on the same day. The company, which has seen its stock surge 61% year-to-date, maintains a strong financial position with a current ratio of 5.35 and more cash than debt on its balance sheet, according to InvestingPro data.
In addition to the amendment, the annual meeting included the election of two directors, Phillip B. Donenberg, CPA, and Sukumar Nagendran, M.D., who will serve until the 2028 annual meeting. Donenberg received 114,260,541 votes in favor and 24,190,378 votes withheld, while Nagendran received 123,281,458 votes in favor and 15,169,461 votes withheld. Broker non-votes totaled 41,164,356. With analyst price targets ranging from $5 to $11 per share, InvestingPro subscribers can access detailed financial analysis and 8 additional ProTips about TSHA’s growth prospects and market position.
The meeting also involved the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal saw 179,419,717 votes in favor, 148,135 against, and 47,423 abstentions, with no broker non-votes.
The announcement and results of the stockholder votes were part of a Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Taysha Gene Therapies has reported significant progress in its development of TSHA-102, a gene therapy for Rett syndrome. The company revealed details of its pivotal trial design, which received alignment from the FDA, allowing for a single-arm, open-label trial with primary endpoints focused on developmental milestone gains. Clinical data from the REVEAL trial indicated that all patients aged 6-21 years achieved at least one developmental milestone post-treatment, with high doses showing superior outcomes and no serious adverse events reported. Cantor Fitzgerald maintained an Overweight rating with a $7 price target, citing promising new data and a clear regulatory pathway as reasons for their confidence. JMP Securities also raised their price target from $5 to $6, highlighting the therapy’s 100% response rate and the FDA’s positive alignment as key factors. Additionally, Taysha announced a public offering of its common stock and pre-funded warrants, managed by Jefferies, BofA Securities, Piper Sandler, and Barclays (LON:BARC). The offering’s details are still subject to market conditions, but it marks a strategic move to advance their gene therapy pipeline. These developments underscore Taysha’s commitment to addressing severe neurological disorders and improving patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.